Brief: Schott Pharma Says Expects Q3 2026 Constant-Currency Revenue Growth Of About 8% And Ebitda Margin Of About 27%
08/07/2026 17:47
BRIEF-Schott Pharma Says Expects Q3 2026 Constant-Currency Revenue Growth Of About 8% And Ebitda Margin Of About 27% July 8 (Reuters) - SCHOTT Pharma AG & Co KgaA 1SXP.DE:
EQS-ADHOC: SCHOTT PHARMA AG & CO. KGAA: SCHOTT PHARMA PUBLISHES PRELIMINARY Q3 KEY FIGURES AND RAISES 2026 REVENUE AND EARNINGS GUIDANCE
SCHOTT PHARMA AG & CO KGAA - EXPECTS Q3 2026 CONSTANT-CURRENCY REVENUE GROWTH OF ABOUT 8% AND EBITDA MARGIN OF ABOUT 27%
SCHOTT PHARMA AG & CO KGAA - RAISED GUIDANCE SUPPORTED BY AGREEMENT WITH KEY CUSTOMER FOR GLASS SYRINGES
SCHOTT PHARMA - FOR 2026, SCHOTT PHARMA EXPECTS CONSTANT-CURRENCY REVENUE GROWTH OF 5% TO 6% AND AN EBITDA MARGIN OF 27% TO 28%
Source text: ID:nEQ3tlXFda
Further company coverage: 1SXP.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SCHOTT Pharma AG & Co. KGaA
See all newsEurope Research Roundup: GSK, Schott Pharma, Vodafone
SCHOTT Pharma rises after J.P. Morgan initiates with 'Overweight'
Schott Pharma rises after Barclays upgrades to 'overweight' on accelerating growth outlook
Europe Research Roundup: Adyen, GYM Group, Rolls Royce
Brief: Schott Pharma - Confirms Recently Increased 2026 Financial Year Guidance